Cybin IncChange company Symbol lookupSelect an option...CYBN Cybin IncTYGO Tigo Energy IncERAS Erasca IncMEOH Methanex CorpCADL Candel Therapeutics IncYECO Yulong Eco-Materials LtdZVOI Zovio IncYEXT Yext IncZNOG Zion Oil and Gas IncPM Philip Morris International IncGo
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
TYGO Tigo Energy Inc
ERAS Erasca Inc
MEOH Methanex Corp
CADL Candel Therapeutics Inc
YECO Yulong Eco-Materials Ltd
ZVOI Zovio Inc
YEXT Yext Inc
ZNOG Zion Oil and Gas Inc
PM Philip Morris International Inc
Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profileBased in Canada
Cybin Inc. (Cybin) is a clinical-stage biopharmaceutical company. The Company is engaged in creating psychedelic-based therapeutics to address the unmet need for new treatment options for people who suffer from mental health conditions. Its development pipeline consists of deuterated psilocybin analog program (CYB003), deuterated dimethyltryptamine program (CYB004), phenethylamine derivatives program (CYB005), and technology programs. The Company is engaged in developing CYB003, a deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The Company's CYB005 is focused on the development of therapeutic phenethylamine derivatives for the treatment of potential neuroinflammation and other neurological conditions. Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings Met Consensus (Q3 ending 12/2022) | Next Earnings Announcement | ||||
|---|---|---|---|---|---|
| Q3 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced February 16, 2023 | -$0.04 | Q3 Estimate range of 5 analysts | -$0.06 to -$0.03 | Q4 Earnings will announce | (Unconfirmed) June 22, 2023 |
Quarterly Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
CYBN's fiscal year ends in March
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.